Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma

• Published in: World journal of surgical oncology Vol. 22; no. 1; pp. 242 - 11
• Main Authors: Chiu, Tai-Jan, Huang, Tai-Lin, Chien, Chih-Yen, Huang, Wan-Ting, Li, Shau-Hsuan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.09.2024; BioMed Central; BMC
• Subjects: Adult; Aged; Aged, 80 and over; Albumin; Biomarkers, Tumor - blood; Calcium; Drug therapy; Female; Follow-Up Studies; Head and neck cancer; Head and Neck Neoplasms - blood; Head and Neck Neoplasms - complications; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - immunology; Head and Neck Neoplasms - pathology; Health aspects; Humans; Hypercalcemia; Hypercalcemia - blood; Hypercalcemia - drug therapy; Hypercalcemia - etiology; Hypoalbuminemia - complications; Hypoalbuminemia - etiology; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Male; Metastasis; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Patient outcomes; Physiological aspects; Prognosis; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Retrospective Studies; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - blood; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - immunology; Squamous Cell Carcinoma of Head and Neck - pathology; Survival Rate; Taiwan; Albumin; Head and neck cancer; Squamous cell carcinoma; Immune checkpoint inhibitors; Calcium

Recent randomized phase III trials have demonstrated the efficacy of anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC). However, a large proportion of such patients still have poor...